Vermillion Developing Two New LDTs with Aim of Early Ovarian Cancer Detection | GenomeWeb

NEW YORK (GenomeWeb) – Having recently rebranded itself as a "bio-analytical solutions company," Vermillion is seeking to move beyond proteomics and incorporate other sources of data into its test offerings with the ultimate aim of developing diagnostics for the early detection of ovarian cancer in high-risk populations, CEO Valerie Palmieri told GenomeWeb this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

Sponsored by

This webinar will discuss a partnership model for noninvasive prenatal testing that enabled LifeLabs Genetics, a genetic testing lab based in Toronto, Ontario, to implement NIPT in house.